Skip to main content
Till KTH:s startsida Till KTH:s startsida

Publications by Torbjörn Gräslund

Peer reviewed

Articles

[2]
S. Pinto et al., "Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide," Journal of Controlled Release, vol. 366, pp. 621-636, 2024.
[3]
S. M. Deyev et al., "Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion," International Journal of Molecular Sciences, vol. 25, no. 8, 2024.
[4]
W. Yin et al., "Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs," Journal of Controlled Release, vol. 355, pp. 515-527, 2023.
[19]
S. M. Deyev et al., "Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1," International Journal of Biological Macromolecules, vol. 145, pp. 216-225, 2020.
[24]
M. Altai et al., "Affibody-derived drug conjugates : Potent cytotoxic molecules for treatment of HER2 over-expressing tumors," Journal of Controlled Release, vol. 288, pp. 84-95, 2018.
[26]
S. Ståhl et al., "Affibody Molecules in Biotechnological and Medical Applications," Trends in Biotechnology, vol. 35, no. 8, pp. 691-712, 2017.
[27]
T. Gräslund, "Affibody molecules : therapy and in vivo diagnostic applications," New Biotechnology, vol. 33, pp. S48-S48, 2016.
[29]
M. Altai et al., "Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin," International Journal of Oncology, vol. 49, no. 3, pp. 1185-1194, 2016.
[33]
J. Seijsing et al., "An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 48, pp. 17110-17115, 2014.
[37]
L. M. Orre et al., "S100A4 interacts with p53 in the nucleus and promotes p53 degradation," Oncogene, vol. 32, no. 49, pp. 5531-5540, 2013.
[40]
K. Larsson et al., "Novel antigen design for the generation of antibodies to G-protein-coupled receptors," JIM - Journal of Immunological Methods, vol. 370, no. 1-2, pp. 14-23, 2011.
[44]
J. Li et al., "Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor," Biotechnology and applied biochemistry, vol. 55, pp. 99-109, 2010.
[46]
E. Lundberg, H. Brismar and T. Gräslund, "Selection and characterization of Affibody (R) ligands to the transcription factor c-Jun," Biotechnology and applied biochemistry, vol. 52, pp. 17-27, 2009.
[47]
E. Vernet et al., "Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule," Journal of immunological methods, vol. 338, pp. 1-6, 2008.
[48]
E. Lundberg et al., "A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase," JIM - Journal of Immunological Methods, vol. 322, no. 1-2, pp. 40-49, 2007.
[49]
R. M. Gordley et al., "Evolution of programmable zinc finger-recombinases with activity in human cells," Journal of Molecular Biology, vol. 367, no. 3, pp. 802-813, 2007.
[50]
[52]
T. Gräslund et al., "Exploring strategies for the design of artificial transcription factors," Journal of Biological Chemistry, vol. 280, no. 5, pp. 3707-3714, 2005.
[53]
M. Hedhammar, T. Gräslund and S. Hober, "Protein engineering strategies for selective protein purification," Chemical Engineering & Technology, vol. 28, no. 11, pp. 1315-1325, 2005.
[54]
M. Linhult et al., "Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach," Proteins : Structure, Function, and Bioinformatics, vol. 55, no. 2, pp. 407-416, 2004.
[55]
M. Hedhammar et al., "Negatively charged purification tags for selective anion-exchange recovery," Protein Engineering Design & Selection, vol. 17, no. 11, pp. 779-786, 2004.
[59]
T. Gräslund et al., "Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner," Journal of Chromatography A, vol. 942, no. 1-2, pp. 157-166, 2002.
[61]
T. Gräslund et al., "Charge engineering of a protein domain to allow efficient ion-exchange recovery," Protein Engineering, vol. 13, no. 10, pp. 703-709, 2000.
[63]
T. Gräslund et al., "Production of a Thermostable DNA Polymerase by Site-Specific Cleavage of a Heat-Eluted Affinity Fusion Protein," Protein Expression and Purification, vol. 9, pp. 125-132, 1997.

Non-peer reviewed

Articles

[64]
O. Thomas et al., "Epstein Barr Virus molecular mimicry to Anoctamin 2 : exploring dual T cell specificities," Multiple Sclerosis Journal, vol. 29, pp. 36-37, 2023.
[65]
A. Vorobyeva et al., "Evaluation of influence of albumin binding domain position on biodistribution of HER2-targeting DARPin-DM1 drug conjugates using radiolabeling," European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. SUPPL 1, pp. S772-S773, 2023.
[66]
A. Vorobyeva et al., "Evaluation of influence of cytotoxic payload on biodistribution of HER2-targeting affibody-drug conjugates using a radioactive label," European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. SUPPL 1, pp. S282-S282, 2022.
[67]
S. Rinne et al., "HER3-targeted drug delivery : Preclinical characterization of (HE)3-ZHER3-ABD-mcDM1 using Tc-99m," European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. SUPPL 1, pp. S654-S655, 2022.
[69]
O. Thomas et al., "Re-visiting alpha beta-crystallin : EBNA1 antibody crossreactivity and CRYAB-specific T cell responses in multiple sclerosis," Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 233-234, 2022.
[70]
O. Thomas et al., "Comprehensive autoantigen panel to determine individual immune profiles in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 50-51, 2021.
[71]
T. Xu et al., "Imaging-guided co-targeting of HER2 and EpCAM using trastuzumab and DARPin-toxin fusion protein for theranostics of ovarian cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, pp. S69-S69, 2021.
[72]
A. Vorobyeva et al., "Selection of Optimal Radiolabel Position and Composition in DARPin Ec1 for High-Contrast Imaging of EpCAM Expression in Prostate Cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, pp. S19-S19, 2021.
[73]
M. Bronge et al., "T cell reactivity screening reveals four novel CNS autoantigens in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 344-345, 2021.
[74]
T. Xu et al., "Evaluation of Molecular Design of HER2-targeting Affibody-drug Conjugates for Drug Delivery to Ovarian Cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, pp. S10-S10, 2020.
[75]
M. Altai et al., "Evaluation Of Several Newly Designed Affibody-based Drug Conjugates Using Radionuclide-based Techniques : A Powerful Tool For Drug Development," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S715-S716, 2019.
[76]
A. Vorobyeva et al., "Imaging of EpCAM expression in pancreatic cancer using radiolabelled DARPin Ec1," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S749-S750, 2019.
[77]
M. Altai et al., "Improving of molecular design of a novel Affibody-fused HER2-recognising anticancer toxin using radionuclide-based techniques," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, pp. S178-S178, 2016.
[78]
V. Tolmachev et al., "HEHEHE : a new chelator for [Tc-99m(CO)(3)](+)-labeling assembling His(6)-tag in protein purification," Nuclear Medicine and Biology, vol. 37, no. 6, pp. 698-698, 2010.
[79]
L. M. Orre et al., "FUNCTIONAL STUDIES OF S100A6 USING PROTEOMICS," Anticancer Research, vol. 28, no. 5C, pp. 3430-3431, 2008.

Other

Patents

Patents

[94]
R. Lewensohn et al., "S100a6 and/or s100a4 inhibitors for treating cancer," WO 2009109862A3, 2008.
[95]
T. Gräslund et al., "IGF-1R binding polypeptides and their use," us 8426557B2 (2013-04-23), 2007.
Latest sync with DiVA:
2024-05-26 01:53:13